News InflaRx N.V.

Equities

IFRX

NL0012661870

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1.41 ^USD	+2.92%		+3.68%	-13.50%

21/03	Transcript : InflaRx N.V. - Special Call
21/03	InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024	30/04	AQ
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed	26/04	PU
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K	26/04	PU
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event	24/04	AQ
Transcript : InflaRx N.V. - Special Call	21/03
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
InflaRx N : News Conference Call March 2024	21/03	PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	21/03	AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	19/03	AQ
InflaRx Appoints Jan Medina as Head of Investor Relations	22/02	AQ
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations	22/02	CI
HC Wainwright Adjusts Price Target on InflaRx to $8 From $9, Keeps Buy Rating	25/01	MT
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients	25/01	GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904	04/01	CI
Transcript : InflaRx N.V. - Special Call	04/01
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904	04/01	AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	06/11	AQ
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	06/11	CI
Top Premarket Gainers	03/11	MT
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update	01/11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News InflaRx N.V.

Equities

IFRX

NL0012661870

Summary

Filters